Literature DB >> 21353784

Development of sulfonamide AKT PH domain inhibitors.

Ali Md Ahad1, Song Zuohe, Lei Du-Cuny, Sylvestor A Moses, Li Li Zhou, Shuxing Zhang, Garth Powis, Emmanuelle J Meuillet, Eugene A Mash.   

Abstract

Disruption of the phosphatidylinositol 3-kinase/AKT signaling pathway can lead to apoptosis in cancer cells. Previously we identified a lead sulfonamide that selectively bound to the pleckstrin homology (PH) domain of AKT and induced apoptosis when present at low micromolar concentrations. To examine the effects of structural modification, a set of sulfonamides related to the lead compound was designed, synthesized, and tested for binding to the expressed PH domain of AKT using a surface plasmon resonance-based competitive binding assay. Cellular activity was determined by means of an assay for pAKT production and a cell killing assay using BxPC-3 cells. The most active compounds in the set are lipophilic and possess an aliphatic chain of the proper length. Results were interpreted with the aid of computational modeling. This paper represents the first structure-activity relationship (SAR) study of a large family of AKT PH domain inhibitors. Information obtained will be used in the design of the next generation of inhibitors of AKT PH domain function.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353784      PMCID: PMC3088502          DOI: 10.1016/j.bmc.2011.01.049

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  34 in total

1.  Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains.

Authors:  Benchun Miao; Igor Skidan; Jinsheng Yang; Alexey Lugovskoy; Mikhail Reibarkh; Kai Long; Tres Brazell; Kulbhushan A Durugkar; Jenny Maki; C V Ramana; Brian Schaffhausen; Gerhard Wagner; Vladimir Torchilin; Junying Yuan; Alexei Degterev
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

2.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.

Authors:  H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

3.  PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase.

Authors:  J Chung; T C Grammer; K P Lemon; A Kazlauskas; J Blenis
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

4.  Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.

Authors:  Emmanuelle J Meuillet; Daruka Mahadevan; Hariprasad Vankayalapati; Margareta Berggren; Ryan Williams; Amy Coon; Alan P Kozikowski; Garth Powis
Journal:  Mol Cancer Ther       Date:  2003-04       Impact factor: 6.261

5.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

Authors:  D R Alessi; S R James; C P Downes; A B Holmes; P R Gaffney; C B Reese; P Cohen
Journal:  Curr Biol       Date:  1997-04-01       Impact factor: 10.834

6.  Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues.

Authors:  S Sianna Castillo; John Brognard; Pavel A Petukhov; Chunyu Zhang; Junji Tsurutani; Courtney A Granville; Min Li; Michael Jung; Kip A West; Joell G Gills; Alan P Kozikowski; Phillip A Dennis
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

7.  Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change.

Authors:  Christine C Milburn; Maria Deak; Sharon M Kelly; Nick C Price; Dario R Alessi; Daan M F Van Aalten
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

8.  Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Authors:  Lin Yang; Han C Dan; Mei Sun; Qiyuan Liu; Xia-meng Sun; Richard I Feldman; Andrew D Hamilton; Mark Polokoff; Santo V Nicosia; Meenhard Herlyn; Said M Sebti; Jin Q Cheng
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

Review 9.  Unravelling the activation mechanisms of protein kinase B/Akt.

Authors:  Michael P Scheid; James R Woodgett
Journal:  FEBS Lett       Date:  2003-07-03       Impact factor: 4.124

Review 10.  The protein kinase B/Akt signalling pathway in human malignancy.

Authors:  Karleen M Nicholson; Neil G Anderson
Journal:  Cell Signal       Date:  2002-05       Impact factor: 4.315

View more
  6 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

2.  Accurate prediction of the bound form of the Akt pleckstrin homology domain using normal mode analysis to explore structural flexibility.

Authors:  Hoang T Tran; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-08-25       Impact factor: 4.956

Review 3.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.

Authors:  Chia-Hsin Chan; John Kenneth Morrow; Chien-Feng Li; Yuan Gao; Guoxiang Jin; Asad Moten; Loren J Stagg; John E Ladbury; Zhen Cai; Dazhi Xu; Christopher J Logothetis; Mien-Chie Hung; Shuxing Zhang; Hui-Kuan Lin
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

5.  Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells.

Authors:  Lu Chen; Lei Du-Cuny; Sylvestor Moses; Sabrina Dumas; Zuohe Song; Abdol Hossein Rezaeian; Hui-Kuan Lin; Emmanuelle J Meuillet; Shuxing Zhang
Journal:  PLoS Comput Biol       Date:  2015-01-08       Impact factor: 4.475

6.  The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors.

Authors:  Aifu Lin; Qingsong Hu; Chunlai Li; Zhen Xing; Guolin Ma; Cheng Wang; Jun Li; Yin Ye; Jun Yao; Ke Liang; Shouyu Wang; Peter K Park; Jeffrey R Marks; Yan Zhou; Jianwei Zhou; Mien-Chie Hung; Han Liang; Zhibin Hu; Hongbing Shen; David H Hawke; Leng Han; Yubin Zhou; Chunru Lin; Liuqing Yang
Journal:  Nat Cell Biol       Date:  2017-02-20       Impact factor: 28.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.